Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (DE:8NE)
FRANKFURT:8NE
RESEARCH TOOLSreports
Holding DE:8NE?
Track your performance easily
8NE Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.74 - €3.34
Previous Close€2.46
Volume0.00
Average Volume (3M)N/A
Market Cap
€22.57M
Enterprise Value-€12.26M
Total Cash (Recent Filing)$38.26M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 07, 2024EPS Estimate
-€0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding8,319,600
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.58
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.71
Forecast
1Y Price Target
€13.54Price Target Upside450.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Lisata Therapeutics News
8NE FAQ
What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest stock price was €1.74 and its highest was €3.34 in the past 12 months.
What is Lisata Therapeutics’s market cap?
Currently, no data Available
When is Lisata Therapeutics’s upcoming earnings report date?
Lisata Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 67 days.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on Aug 12, 2024. The company reported -€0.551 earnings per share for the quarter, beating the consensus estimate of -€0.677 by €0.126.
Is Lisata Therapeutics overvalued?
According to Wall Street analysts Lisata Therapeutics’s price is currently Undervalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics does not currently pay dividends.
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate is -€0.68.
How many shares outstanding does Lisata Therapeutics have?
Lisata Therapeutics has 8,319,600 shares outstanding.
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -€0.551 in its last earnings report, beating expectations of -€0.677. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Among the largest hedge funds holding Lisata Therapeutics’s share is RA Capital Management. It holds Lisata Therapeutics’s shares valued at N/A.
---
Lisata Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.19%
12-Months-Change
Fundamentals
Return on Equity
-43.80%
Trailing 12-Months
Asset Growth
-31.74%
Trailing 12-Months
Company Description
Lisata Therapeutics
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
---
8NE Company Deck
---
8NE Earnings Call
Q2 2024
0:00 / 0:00
---
8NE Stock 12 Month Forecast
Average Price Target
€13.54
▲(450.40% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Illumina
―
Vertex Pharmaceuticals
―
Lisata Therapeutics
―
Best Analysts Covering 8NE
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+5.79%
reiterated a buy rating 19 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +5.79% per trade.
---